RESEARCH ARTICLE

REVISED Biochemical and clinical characterization of metabolic phenotypes: a cross-sectional study from Maracaibo city, Venezuela [version 2; peer review: 1 approved, 1 not approved]

Valmore Bermudez ^{1,2}, Joselyn Rojas^{2,3}, Juan Salazar ², Maria Sofia Martinez², Luis Carlos Olivar², Maria Jose Calvo², Andres Mindiola⁴, Roberto Añez ², Sandra Wilches-Duran¹, Marcos Cerda¹, Modesto Graterol¹, Rosemily Graterol¹, Juan Diego Hernandez¹, Carlos Garicano¹, Manuel Velasco⁵

¹Grupo de Investigación Altos Estudios de Frontera (ALEF), Universidad Simón Bolívar, Cucuta, Colombia

²Endocrine and Metabolic Diseases Research Center, The University of Zulia, Maracaibo, Venezuela

³Pulmonary and Critical Care Medicine Department, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

⁴Geriatric Research Education and Clinical Center (GRECC), U.S Department of Veterans Affairs, Miami, FL, USA

⁵Department of Pharmacology, "JM Vargas" Medical School, Central University of Venezuela, Caracas, Venezuela

v2 First published: 27 Feb 2018, 7:230
<https://doi.org/10.12688/f1000research.13897.1>
 Second version: 04 Jan 2019, 7:230
<https://doi.org/10.12688/f1000research.13897.2>
 Latest published: 24 Mar 2021, 7:230
<https://doi.org/10.12688/f1000research.13897.3>

Abstract

Background: In 1980, Reuben Andresen observed that in certain individuals, obesity did not increase mortality, introducing an atypical phenotype called "healthy obese". Other studies reported that 10-15 % of lean individuals presented insulin resistance, hyperglycemia and dyslipidemia. The objective of this study was to evaluate biochemical and clinical characteristics of metabolic phenotypes in Maracaibo city.

Methods: A descriptive, cross-sectional sub-analysis of The Maracaibo City Metabolic Syndrome Prevalence Study, with a randomized multistage sampling was performed including 1226 non diabetic individuals from both sexes. For phenotype definition, the subjects were first classified according to their BMI into Normal-Weight, Overweight and Obese; then divided in metabolically healthy and unhealthy using a two-step analysis cluster being predictive variables: HOMA2-IR, HOMA2-βcell, triglycerides. To evaluate the relationship with coronary risk, a multiple logistic regression model was performed.

Results: In the studied population, 43.9% (n=538) were healthy normal weight, 5.2% (n=64) unhealthy normal weight, 17.4% (n=217) healthy obese and 33.5% (n=411) unhealthy obese subjects. Atypical

Open Peer Review

Approval Status

	1	2	3
version 3			
(revision)			
24 Mar 2021		view	view
version 2			
(revision)			
04 Jan 2019	view	view	
version 1			
27 Feb 2018			
	view		

1. **Víctor A. Cortes** , Pontifical Catholic University of Chile (UC), Santiago, Chile
2. **Manfred J. Müller**, Christian Albrechts Universität zu Kiel, Kiel, Germany
3. **Hannah XY Hui** , The Chinese University

phenotypes, Metabolically Unhealthy Normal-Weight (MUNW) was more frequent in males (56.3%), whereas Metabolically Unhealthy Obese (MUO) was more frequent in females (51.3%). This phenotypes had a higher coronary event risk, especially for obese individuals (MHO: OR=1.85 CI95%: 1.11-3.09; $p=0.02$ and MUO: OR=2.09 CI95%: 1.34-3.28; $p<0.01$).

Conclusion: Individuals with atypical metabolic phenotypes are common in Maracaibo city. Related factors may include insulin resistance, basal glucose, and triglycerides levels. Lastly, obese subjects show a higher coronary event risk even those with normal metabolic status.

Keywords

Metabolic phenotypes, two-step cluster, metabolically unhealthy lean, metabolically healthy obese, coronary risk

of Hong Kong, Hong Kong, China

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding authors: Valmore Bermudez (valmore@gmail.com), Juan Salazar (juanjsv18@hotmail.com)

Author roles: **Bermudez V:** Conceptualization, Writing – Review & Editing; **Rojas J:** Conceptualization, Writing – Review & Editing; **Salazar J:** Formal Analysis, Writing – Original Draft Preparation; **Martinez MS:** Formal Analysis, Writing – Original Draft Preparation; **Olivar LC:** Data Curation, Investigation; **Calvo MJ:** Data Curation, Investigation; **Mindiola A:** Investigation, Writing – Original Draft Preparation; **Añez R:** Data Curation, Formal Analysis; **Wilches-Duran S:** Funding Acquisition, Writing – Review & Editing; **Cerda M:** Funding Acquisition, Writing – Original Draft Preparation; **Graterol M:** Formal Analysis, Funding Acquisition; **Graterol R:** Funding Acquisition, Writing – Original Draft Preparation; **Hernandez JD:** Formal Analysis, Investigation; **Garicano C:** Investigation, Writing – Original Draft Preparation; **Velasco M:** Investigation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by research grant N° CC-0437-10-21-09-10 from the Technological, Humanistic, and Scientific Development Council (Consejo de Desarrollo Científico, Humanístico y Tecnológico; CONDES), University of Zulia. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2019 Bermudez V *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Bermudez V, Rojas J, Salazar J *et al.* **Biochemical and clinical characterization of metabolic phenotypes: a cross-sectional study from Maracaibo city, Venezuela [version 2; peer review: 1 approved, 1 not approved]** F1000Research 2019, 7:230 <https://doi.org/10.12688/f1000research.13897.2>

First published: 27 Feb 2018, 7:230 <https://doi.org/10.12688/f1000research.13897.1>

REVISED Amendments from Version 1

1. In the "Abstract" section: all data requested in methodology were added (concisely as it would carry a large number of words). The results were edited in order to improve the understanding regarding the frequency of each phenotype. The conclusion was also edited to facilitate comprehension according to the reviewer's suggestion.
2. The Introduction section was edited and expanded.
3. In the methodology section, population selection was edited, for both, improving its comprehension, and explaining that cluster analysis was conducted to select the healthy and sick subjects. However, we consider that it is important to be maintained for the description of certain methodological details as well as the variables included in the analysis.
4. Regarding physical activity, table 1 was eliminated and physical activity domains were reclassified into 2 categories (Inactive and active) to simplify the analysis and description of the physical activity throughout the work.
5. In relation to the Framingham-Wilson calibrated equation, the drafting was edited and improved. Asymptomatic events are in reference to myocardial infarction only excluding angina events.
6. In Table 2, we change "Indian-American" for "Native American".
7. A post-hoc analysis of the differences between the quantitative variables of Table 6 (now Table 5) was added. The description was detailed on the basis of these findings.
8. The section "metabolic phenotypes and coronary risk classification" was edited, highlighting positive result only in obese subjects.

See referee reports

Introduction

Obesity is considered an entity with major morbi-mortality in the world since the end of the 20th century¹. Multiples studies have shown its role as an independent risk factor for various cardiometabolic disorders such as hypertension (HTN), dyslipidemias, Type 2 Diabetes Mellitus (T2DM) and cardiovascular disease (CVD)². For this reason, the actual clinical practice catalogues the typical obese patient as an "unhealthy" patient or a patient with comorbidities.

In spite of this, in 1980, Reuben Andresen discovered that in certain groups of individuals the obesity was not a mortality increasing factor, introducing the subtype "Healthy Obese"³. Around 20 years later, Ferranini *et al.* observed that a group of certain obese nondiabetic non-hypertensive subjects presented low insulin resistance (IR) prevalence, suggesting that this subtype must have a different risk of having T2DM and CVD from the IR obese; also suggesting a different management for them⁴.

Furthermore, in 1975, Bernstein *et al.* observed that 11 normal-weight men with type IV or V dyslipidemia presented higher serum glucose levels; and also carried bigger sized adipocytes with respect to their healthy counterparts⁵. Years later, Ruderman *et al.* introduced the "Metabolically Unhealthy Normal-Weight" phenotype attributed to lean individuals with metabolic alterations associated to obesity⁶.

The importance of these atypical metabolic phenotypes lies in the fact that their diagnosis may be challenging for clinicians delaying their detection. Because of this, in recent years, multiple studies have been dedicated to the research of accurate clinical, biochemical, and genetic elements capable to detect these atypical metabolic states, and their evolution. Likewise, it has been discussed whether the use of certain anthropometric parameters is enough to classify the subjects as healthy or sick from a cardiometabolic perspective.

In this sense, these phenotypes determinants and frequencies have not been deeply researched in Latin-American populations⁷. Despite the wide heterogeneity observed in our region influenced for genetic and environmental factors as well as the similar prevalence of cardiometabolic diseases in Maracaibo city and other localities from the continent. The objective of this study is to characterize, from a clinical-biological point of view, the metabolic phenotypes in the population from Maracaibo city, Venezuela.

Materials and methods

Population selection

The Maracaibo City Metabolic Syndrome Prevalence Study (MMSPS) is a cross-sectional study whose purpose is to detect metabolic syndrome and cardiovascular disease risk factors in the adult population from Maracaibo, the second largest city of Venezuela, with approximately 2,500,000 inhabitants, during the period May 2007 – December 2009. The original study included a total of 2230 individuals of both genders, aged between 18–85 years old, and the study protocol was previously reported⁸. This sub-analysis excluded those individuals with no measurements of serum insulin levels. Patients with past history of diabetes were also excluded because their disease control, evolution and pharmacological treatments would affect the variables in the study.

In order to avoid classifying the subjects according to *a priori* pre-established definitions, a cluster analysis was carried out that allowed selecting the main variables in the definition of healthy-sick subjects by data mining technique. In this way, these subjects were categorized into six groups, first according to their Body Mass Index (BMI) (normal-weight, overweight and obese) and second, to their healthy/unhealthy definition. This categorization was made using the protocol from two-step cluster analysis published previously⁹. The metabolic variables were chosen as possible metabolic predictors based on their physiological function and biological plausibility. These variables were: mean arterial pressure (MAP), triglycerides (TAG), total cholesterol, HDL-C, HOMA2-IR, HOMA2-βcell, HOMA2-S, fasting blood glucose, non-HDL-C cholesterol, TAG/HDL-C ratio, and high-sensitivity C-Reactive Protein (hs-CRP) levels; waist circumference (WC) was excluded and was assessed as a dependent variable.

The most appropriate predictive variables selected, according predictive strength for each group were: (a) HOMA2-IR and HOMA2-βcell for normal-weight women; (b) HOMA2-IR, HOMA2-βcell and TAG for normal-weight men; (c) HOMA2-IR

and HOMA2- β cell for overweight women; (d) HOMA2-IR, HOMA2- β cell, and TAG for overweight men; and (e) HOMA2-IR for male and female obese patients. The two-step cluster analysis was conducted with SPSS, the program analyzed the subclusters with the characteristics of each BMI category and categorized the subjects into 6 phenotypes: healthy normal-weight (HNW), metabolically unhealthy normal-weight (MUNW), healthy and metabolically disturbed overweight, metabolically unhealthy obese (MUO), and metabolically healthy obese (MHO). Overweight subjects were excluded from this secondary analysis since they represent a non-conventional group outside the metabolic phenotypes and require separate analysis. The final sample included 1226 subjects (Figure 1).

Clinical evaluation

Data was collected through completion of a full clinical record carried out by trained personnel, which included interrogation regarding ethnic origin and socioeconomic status by the Graffar scale according to Méndez-Castellano¹⁰. The assessment of

blood pressure was done by applying the auscultatory technique, and HTN classification was made using the criteria proposed in the VII Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure¹¹.

For Anthropometric Analysis, an electrical bioelectric scale was used to obtain weight (Tanita, TBF-310 GS Body Composition Analyzer, Tokyo – Japan). Height was measured using a calibrated metric measurement tape, with the subject standing up barefoot. BMI formula (weight/height²) was applied, expressing the results as kg/m². Obesity was classified applying the WHO criteria¹² based on the BMI value. Finally, WC was measured using calibrated measuring tape in accordance to the anatomical landmarks proposed by the USA National Institutes of Health protocol¹³.

Physical activity. Physical activity (PA) was assessed with the International Physical Activity Questionnaire (IPAQ). For statistical analysis, PA was evaluated in 4 domains: occupational,

Figure 1. Patient selection diagram. Maracaibo city, Venezuela. During sample selection, subjects with no measurements of serum insulin levels and patients with past history of diabetes were excluded. These subjects were categorized into six groups, first according to their BMI and second to their healthy/unhealthy definition, using two-step cluster analysis.

household, transport, and leisure. In each of these domains, subjects were categorized as follows: (a) inactive, MET/week = 0, or (b) active, MET/week > 0.

Biochemical analyses

Fasting levels of glucose, cholesterol, TAG, HDL-C, and hs-CRP were assessed in our clinical laboratory using an automatized computer analyzer (Human Gesellschaft für Biochemica und Diagnostica mbH). LDL-C and VLDL-C levels were calculated applying the Friedewald formulas¹⁴. When TAG were over 400 mg/dL measurement was done using lipoprotein electrophoresis and optical densitometry (BioRad GS-800 densitometer, USA). Lipoprotein (a) [Lp(a)] was estimated through the latex turbidimetric method, Human Gesellschaft für Biochemica und Diagnostica, Germany. Likewise, serum hs-CRP levels were quantified employing immunoturbidimetric essays (Human Gesellschaft für Biochemica und Diagnostica MBH). Insulin was determined using an ultrasensitive ELISA method (DRG Instruments GmbH, Germany, International DRG Division, Inc.). For the evaluation of insulin resistance (IR), 2 was the cut-off to define it¹⁵, the HOMA2-IR model proposed by Levy *et al.* was utilized¹⁶ determined through the HOMA-Calculator v2.2.2 program. Visceral Adiposity Index (VAI) calculation was performed with the gender-specific equations proposed by Amato *et al.*¹⁷. The Metabolic Syndrome (MS) diagnosis was done using the Harmonizing-2009 consensus criteria¹⁸.

Calibration of the Framingham-Wilson equation and coronary risk categorization for the population of Maracaibo city

For proper equation calibration, the constants in the formula regarding major cumulative coronary events (lethal and non-lethal, symptomatic and no symptomatic myocardial infarction, angina) were substituted with the local statistics obtained from the Vital Statistics Yearbook of the State of Zulia from 2008, where the morbidity and mortality for cardiovascular diseases is registered, the calibration process has been detailed previously¹⁹. The coronary risk was classified in 2 categories: <5% in 10 years, and ≥5% in 10 years.

Statistical analysis

Normal distribution of continuous variables was assessed using Geary's test; for normally distributed variables, the results were expressed as arithmetic mean ± SD (standard deviation). Variables without normal distribution were logarithmically transformed, and normal distribution subsequently corroborated. When normalization could not be achieved, these variables were expressed as medians (25th percentile–75th percentile). Student's *t*-test/One-way ANOVA or Mann-Whitney/Kruskal Wallis's tests were applied to evaluate differences between means or medians, respectively. Qualitative variables were expressed as absolute and relative frequencies, assessed through the χ^2 test and the Z test for Proportions.

A logistic regression model was constructed with coronary risk as dependent variable and independent variables: gender, age groups, ethnicity, socioeconomic status, smoking habit, physical activity in leisure time, elevated TAG, and metabolic phenotypes.

Database construction and statistical analysis were done using the Statistical Package for the Social Sciences (SPSS) v22 for Windows (IBM Inc., Chicago, IL), results were considered statistically significant when $p < 0.05$.

Results

Population general characteristics

A total of 1226 individuals were studied, 55.1% (n=676) corresponded to females and 44.9% (n=550) to males. The mean age (years) of the general population was 37.94 ± 14.99 . Subjects distribution according to their metabolic phenotype is shown in **Figure 2** where the 5.2% (n=64) of the individuals were classified as MUNW, and 17.4% (n=213) as MHO, representing 34.13% from the total of obese subjects, while sociodemographic and metabolic characteristics from the studied sample are shown in **Table 1**.

Metabolic phenotypes and sociodemographic characteristics

In the evaluation of the epidemiologic behavior of the metabolic phenotypes according to sex, we found that HNW and MUO individuals were predominately females (62.5%, n=336; 51.3%, n=211 respectively), while the atypical phenotypes were predominately males (MUNW: 56.3%, n=36; MHO: 52.6%, n=112. $\chi^2=22.53$, $p < 0.001$). Likewise, a statistically significant association was found between age groups and metabolic phenotypes ($\chi^2=211.91$, $p < 0.001$), observing a predominance in the < 30 years age group in the normal-weight phenotype (HNW: 56.1%, n=302; MUNW: 57.8%, n=37), whereas the 30–49 age group was predominately obese phenotypes (MHO: 47.9%, n=102; MUO: 50.1%, n=106). There was no statistically significant association between metabolic phenotypes, ethnic groups ($\chi^2=20.96$, $p=0.05$) and socioeconomic status ($\chi^2=14.56$, $p=0.27$) (**Table 2**).

Metabolic phenotypes and psychobiologic habits

Initially, in relation to the smoking habit, the non-smokers were the most frequent group ($\chi^2=30.91$; $p < 0.001$), despite the fact MUNW phenotype consisted of the highest percentage of

Healthy Normal-Weight: n=538 (43.9%)	Metabolically Unhealthy Normal-Weight: n=64 (5.2%)
Metabolically Healthy Obese: n=213 (17.4%)	Metabolically Unhealthy Obese: n=411 (33.5%)

Figure 2. Distribution of individuals according to metabolic phenotypes. Maracaibo city, Venezuela. For this sub-analysis overweight subjects were excluded, evaluating only the typical obesity phenotypes with 4 groups.

Table 1. General Characteristics of the studied sample.
Maracaibo city, Venezuela.

	Female		Male		Total	
	n	%	n	%	n	%
Age Group (years)						
<30	235	34.8	228	41.5	463	37.8
30–49	253	37.4	220	40.0	473	38.6
≥50	188	27.8	102	18.5	290	23.7
Ethnic Groups						
Mixed	512	75.7	427	77.6	939	76.6
White Hispanic	111	16.4	80	14.5	191	15.6
Afrodescendant	15	2.2	21	3.8	36	2.9
Native-American	30	4.4	21	3.8	51	4.2
Other	8	1.2	1	0.2	9	0.7
Socioeconomic Status						
Class I	15	2.2	9	1.6	24	2.0
Class II	116	17.2	113	20.5	229	18.7
Class III	253	37.4	237	43.1	490	40.0
Class IV	251	37.1	172	31.3	423	34.5
Class V	41	6.1	19	3.5	60	4.9
Smoking Habit						
No Smoker	523	77.5	351	64.3	874	71.6
Smoker	76	11.3	105	19.2	181	14.8
Past Smoker	76	11.3	90	16.5	166	13.6
Hypertension†	126	18.6	144	26.2	270	22.0
Elevated Triglycerides	139	20.6	170	30.9	309	25.2
Low HDL-C	429	63.5	270	49.1	699	57.0
Metabolic Syndrome*	250	37.0	233	42.4	483	39.4
Insulin Resistance†	317	46.9	257	46.7	574	46.8
Total	676	100.0	550	100.0	1226	100.0

† Past history and Diagnosed in the Study

* Metabolic Syndrome Diagnosis according to 2009 Harmonizing Consensus

† HOMA2-IR ≥2

smoking individuals (18.8%, n=12), whereas MUO subjects consisted of the highest proportion of past smoking subjects (20.2%, n=83). On the other side, in the evaluation of the metabolic phenotypes according to PA there was a statistically significant association in the transport-related physical activity ($\chi^2=26.93$; $p<0.001$) and leisure activities ($\chi^2=19.75$; $p<0.001$) (Table 3).

Phenotypes and endocrine-metabolic alterations

Distribution of subjects according to phenotypes and endocrine-metabolic alterations are shown in Table 4. A high percentage of

MUNW and MUO individuals with insulin resistance was found in contrast to healthy subjects (79.7%, n=51 and 97.1%, n=399, respectively). On the other side, a higher percentage of MUNW with high TAG was found (34.4% n=22 vs 9.5% n=51 HNW; $p<0.05$) and also a higher prevalence of MS (29.7% n=19 vs 12.3% n=66; $p<0.05$ HNW); similar findings were observed in the obese phenotypes, where a minor prevalence of these alterations were found in the MHO subjects (high TAG levels: 28.8% n=60 vs 42.8% n=176, $p<0.05$; MS: 53.1% n=113 vs 69.3% n=285, $p<0.05$). Finally, a significant association was found between the metabolic phenotypes with low HDL-C ($\chi^2=44.08$; $p<0.0001$) and HTN ($\chi^2=182.22$, $p<0.0001$).

Metabolic phenotypes and biologic-anthropometric variables

Biochemical and clinical characteristics according to metabolic phenotypes are shown in Table 5. An increasing tendency of their variable levels was observed, except on HOMA2-IR, HOMA2-βcell, HOMA2-S, insulin and glucose levels whose values were higher in sick subjects; while individuals with obesity had lower levels of HDL-C.

Metabolic phenotypes and coronary risk classification

An association between metabolically unhealthy phenotypes and a higher risk of a coronary event was found in univariate analysis. However, results were statistically significant only for obese individuals when multivariate adjustment was applied (MHO: OR=1.85 CI95%: 1.11-3.09; $p=0.02$ and MUO: OR=2.09 CI95%: 1.34-3.28; $p<0.01$) (Table 6).

Dataset 1. MMSPS metabolic phenotype dataset

<http://dx.doi.org/10.5256/f1000research.13897.d193351>

BMI: Body Mass Index, WaistC: Waist Circumference, HDL-C: High Density Lipoprotein Cholesterol, VLDL-C: Very Low Density Lipoprotein Cholesterol, LDL-C: Low Density Lipoprotein Cholesterol, Lp(a): Lipoprotein (a), hs-CRP: high Sensitivity C Reactive Protein, Non-HDL-Col: Non-High Density Lipoprotein Cholesterol, TAG/HDL ratio: Triglycerides/High Density Lipoprotein ratio VAI: Visceral Adiposity Index, BP: Blood Pressure, HNW: Healthy Normal-Weight, MUNW: Metabolically Unhealthy Normal-Weight, MUO: Metabolically Unhealthy Obese, MHO: Metabolically Healthy Obese.

Discussion

Obesity is a prioritized area for the world health systems because of its increasing prevalence, incidence, and associated costs in the last decade²⁰. This disease has been defined classically as “excessive presence of adipose tissue that is injurious for health” and given its association to other chronic-degenerative diseases^{3,21} has been stereotyped as “more adiposity, more risk”. All the classic methods employed for obesity diagnosis, even central and global, are indirect measurements. For different populations they do not allow to determine the adipose tissue functioning from individuals, even though they have high sensitivity, specificity, and predictive values. Based on this, multiple epidemiologic studies have detected a considerable percentage of individuals who did not enter in the classic “HNW” and “MUO” phenotypes, showing the existence of atypical metabolic phenotypes called “MUNW” and “MHO”³. The defining criteria of these metabolic states

Table 2. Sociodemographic characteristics according to metabolic phenotypes. Maracaibo city, Venezuela.

	(HNW) A		(MUNW) B		(MHO) C		(MUO) D		χ^2 (p)*	A vs. B	A vs. C	A vs. D	B vs. C	B vs. D	C vs. D
	n	%	n	%	n	%	n	%		p**	p**	p**	p**	p**	p**
Gender									22.53 (<0.001)						
Female	336	62.5	28	43.8	101	47.4	211	51.3		<0.05	<0.05	<0.05	NS	NS	NS
Male	202	37.5	36	56.3	112	52.6	200	48.7		<0.05	<0.05	<0.05	NS	NS	NS
Age Group (years)									176.63 (<0.001)						
<30	302	56.1	37	57.8	46	21.6	78	19.0		NS	<0.05	<0.05	<0.05	<0.05	NS
30–49	153	28.4	12	18.8	102	47.9	206	50.1		NS	<0.05	<0.05	<0.05	<0.05	NS
≥ 50	83	15.5	15	23.4	65	30.5	127	30.9		NS	<0.05	<0.05	NS	NS	NS
Ethnic Group									20.96 (0.05)						
Mixed	412	76.6	50	78.1	169	79.3	308	74.9		NS	NS	NS	NS	NS	NS
White Hispanic	74	13.8	6	9.4	31	14.6	80	19.5		NS	NS	NS	NS	NS	NS
Afrodescendant	16	3.0	3	4.7	6	2.8	11	2.7		NS	NS	NS	NS	NS	NS
Native-American	32	5.9	5	7.8	6	2.8	8	1.9		NS	NS	<0.05	NS	<0.05	NS
Others	4	0.7	0	0.0	1	0.5	4	1.0		NS	NS	NS	NS	NS	NS
Socioeconomic Status									14.56 (0.27)						
Class I	12	2.2	0	0.0	2	0.9	10	2.4		NS	NS	NS	NS	NS	NS
Class II	96	17.8	15	23.4	35	16.4	83	20.2		NS	NS	NS	NS	NS	NS
Class III	213	39.6	21	32.8	102	47.9	154	37.5		NS	NS	NS	NS	NS	NS
Class IV	187	34.8	25	39.1	62	29.1	149	36.3		NS	NS	NS	NS	NS	NS
Class V	30	5.6	3	4.7	12	5.6	15	3.6		NS	NS	NS	NS	NS	NS
Total	538	100	64	100	213	100	411	100							

HNW (Healthy Normal Weight); MUNW (Metabolically Unhealthy Normal Weight); MHO (Metabolically Healthy Obese); MUO (Metabolically Unhealthy Obese).

* Chi-Square Test.

** Z-test of proportions.

differ significantly between studies and are defined under highly subjectivity levels, nonetheless insulin sensitivity and lipid profile are often used to define healthy and unhealthy phenotypes^{22–24}.

Giving this criteria and methods discrepancy, such as the psychobiologic, sociodemographic, and genetic patterns according

to latitudes, the phenotype frequency presents high variability²⁵. This could bias the study by selecting predetermined variables and cut-off points to consider an individual as healthy or unhealthy. In this sense, data mining techniques were proposed to avoid potential bias. The program would group subjects according to spontaneous tendencies and biologic behavior of related variables.

Table 3. Psychobiologic Habits according to metabolic phenotypes. Maracaibo city, Venezuela.

	(HNW) A		(MUNW) B		(MHO) C		(MUO) D		χ^2 (p)*	A vs. B	A vs. C	A vs. D	B vs. C	B vs. D	C vs. D
	n	%	n	%	n	%	n	%		p**	p**	p**	p**	p**	p**
Smoking Habit									30.91 (<0.001)						
No Smoker	415	77.7	44	68.8	154	72.6	261	63.5		NS	NS	<0.05	NS	NS	NS
Smoker	72	13.5	12	18.8	30	14.2	67	16.3		NS	NS	NS	NS	NS	NS
Past Smoker	47	8.8	8	12.5	28	13.2	83	20.2		NS	NS	<0.05	NS	NS	NS
Physical Activity Work Sphere									0.49 (0.92)						
Inactive	408	75.8	50	78.1	159	74.6	307	74.7		NS	NS	NS	NS	NS	NS
Active	130	24.2	14	21.9	54	25.4	104	25.3		NS	NS	NS	NS	NS	NS
Physical Activity Transport Sphere									26.93 (<0.001)						
Inactive	163	30.6	19	30.2	87	41.0	188	46.4		NS	<0.05	<0.05	NS	NS	NS
Active	369	69.4	44	69.8	125	59.0	217	53.6		NS	<0.05	<0.05	NS	NS	NS
Physical Activity Household Sphere									13.69 (<0.01)						
Inactive	125	23.2	15	23.4	75	35.2	126	30.7		NS	<0.05	NS	NS	NS	NS
Active	413	76.8	49	76.6	138	64.8	285	69.3		NS	<0.05	NS	NS	NS	NS
Physical Activity Leisure Sphere									19.75 (<0.001)						
Inactive	305	56.7	37	57.8	134	62.9	290	70.6		NS	NS	<0.05	NS	NS	NS
Active	233	43.3	27	42.2	79	37.1	121	29.4		NS	NS	<0.05	NS	NS	NS
Total	538	100	64	100	213	100	411	100							

HNW (Healthy Normal Weight); MUNW (Metabolically Unhealthy Normal Weight); MHO (Metabolically Healthy Obese); MUO (Metabolically Unhealthy Obese).

* Chi-Square Test. ** Z-test of proportions.

Applied studies in Asia reported a prevalence of 8.7%–13.07% and 3.9%–15.5% for MUNW and MHO phenotypes, respectively^{26,27}. Likewise, studies conducted in Europe reported frequencies ranging between 18.9% and 45.8% for the MUNW phenotype, and between 2.1% and 18.5% for the MHO phenotype^{28–30}; a similar variability was observed in American research studies^{31,32}. Latin American reports are scant, however Fanghanel *et al.*³³ showed a 5.8% prevalence of the MUNW phenotype for the Mexico City, similar to the one showed in the present study, whereas contrasting the obese phenotypes the Maracaibo population exhibited the highest prevalence of MHO subjects (17% vs 10.8% of the Mexican population).

The atypical metabolic phenotypes, as MUNW and MHO, tend to be observed in females with more frequency^{32,34}. However, the present study reported these phenotypes were more frequent in males. Significant difference between sexes was found in the MUNW group, similar to the study by Hinnouko *et al.*³⁵. Smoking habit, age, and physical activity values, were discovered as influencing factors in these findings.

In the same manner, multiple studies have reported that healthy phenotype prevalence decreases with age^{27,29}, but in our population

an increase was observed in the frequency of MHO individuals older than 30 years old. Yoo *et al.*³⁶ did not report differences in this phenotype prevalence between subjects older and younger than 35 years. Regarding the MUNW phenotype in the Maracaibo population, a higher frequency was found in subjects younger than 30 years. A considerable part of epidemiologic studies that evaluate this association possessed samples conformed by subjects older than 35 years. This may limit the establishment of a tendency in frequency of healthy phenotypes according to age. Similarly, factors such as ethnicity from African descendants³⁷ and socioeconomic status³⁸ have been related to the presence of atypical phenotypes, but no relationship was found between these variables in Maracaibo population.

One of the greatest enigmas formulated in relation to the atypical metabolic phenotypes, is focused on its conditioning factors. Psychobiologic habits have been considered key elements in comprehension of its biology and behavior related to time. Diniz *et al.*³⁹ found a significant association between healthy metabolic phenotypes with absence of smoking habit, also with increased PA levels, such as the present study. Ortega *et al.*⁴⁰ reported that MHO subjects present with better cardiorespiratory fitness profiles than their unhealthy counterpart, and by adjusting for this

Table 4. Endocrine-Metabolic Alterations according to metabolic phenotypes Maracaibo city, Venezuela.

	(HNW) A		(MUNW) B		(MHO) C		(MUO) D		χ^2 (p)*	A vs. B	A vs. C	A vs. D	B vs. C	B vs. D	C vs. D
	n	%	n	%	n	%	n	%		p**	p**	p**	p**	p**	p**
HOMA2-IR									727.9 (<0.0001)						
<2	434	80.7	13	20.3	193	90.6	12	2.9		<0.05	NS	<0.05	NS	<0.05	<0.05
≥ 2	104	19.3	51	79.7	20	9.4	399	97.1		<0.05	<0.05	<0.05	<0.05	<0.05	<0.05
Hypertension									182.22 (<0.0001)						
Absent	331	87.3	32	82.1	53	43.1	96	39.8		NS	<0.05	<0.05	<0.05	<0.05	NS
Present†	48	12.7	7	17.9	70	56.9	145	60.2		NS	<0.05	<0.05	<0.05	<0.05	NS
Triglycerides									142.09 (<0.0001)						
Normal	487	90.5	42	65.6	153	71.8	235	57.2		<0.05	<0.05	<0.05	NS	NS	<0.05
High	51	9.5	22	34.4	60	28.2	176	42.8		<0.05	<0.05	<0.05	NS	NS	<0.05
HDL-C									44.08 (<0.0001)						
Normal	283	52.6	30	46.9	85	39.9	129	31.4		NS	<0.05	<0.05	NS	NS	NS
Low	255	47.4	34	53.1	128	60.1	282	68.6		NS	<0.05	<0.05	NS	NS	NS
Metabolic Syndrome									339.38 (<0.0001)						
Absent	472	87.7	45	70.3	100	46.9	126	30.7		<0.05	<0.05	<0.05	<0.05	<0.05	<0.05
Present	66	12.3	19	29.7	113	53.1	285	69.3		<0.05	<0.05	<0.05	<0.05	<0.05	<0.05
Total	538	100	64	100	213	100	411	100							

HNW (Healthy Normal Weight); MUNW (Metabolically Unhealthy Normal Weight); MHO (Metabolically Healthy Obese); MUO (Metabolically Unhealthy Obese).

* Chi-Square Test.

** Z-test of proportions.

† Personal history and Diagnosis in the Study

variable the MHO individuals showed less mortality. Other studies report that the phenotypes progression from health to unhealthiness is not related to the smoking habit, alcohol, or quantified PA through indirect methods³⁰ and depends fundamentally on abdominal circumference and visceral adiposity increment.

Regarding to cardiometabolic profiles, our study showed evidence of significantly higher HOMA2- β cell values in all of the unhealthy phenotypes, described previously by the NHANES study⁴¹ and by Madeira *et al.*⁴². Also higher HOMA2-IR and a lower HOMA2-S demonstrate again the importance to define metabolic states in lean and obese individuals. They could also elevate the risk of developing T2DM and CVD in the unhealthy

phenotypes, given their hyper functioning pancreatic beta cell and hyperinsulinemia⁴³.

MHO subjects present with lower HOMA2-IR and higher TAG, LDL-C, PAS, PAD, and hs-CRP levels. In contrast to lean subjects, MHO has higher VAI. The latter constitutes an initial obesity state, without a significant risk of T2DM and CVD in the short term (7–11 years)⁴⁴, but there is in the long term (>16–30 years)⁴⁵. The natural history of the MHO is variable, only 16% of MHO individuals stay on that status without alteration for the following 7–8 years⁴⁶. Those who progress to an unhealthy state present a higher risk of high blood pressure, low-grade inflammation, bad metabolic control and high TAG³⁰. In spite of the metabolic

Table 5. Clinical and biochemical characteristics according to metabolic phenotypes. Maracaibo city, Venezuela.

	HNW [A]		MUNW [B]		MHO [C]		MUO [D]			
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	<i>p</i> *	<i>Pos-hoc Analysis</i> §
Age (years)	32,5	14,7	34,1	16,5	42,9	13,5	43,1	13,2	<0.001	C and D > A and B
Body Mass Index (Kg/m²)	21,9	2,1	22,9	1,7	34,5	4,7	35,4	5,6	<0.001	C and D > A and B
Waist Circunference (cm)										
Female	79,3	8,2	77,2	7,1	104,4	10,6	105,5	10,1	<0.001	C and D > A and B
Male	81,5	6,9	86,9	7,6	109,2	11,9	116,0	15,3	<0.001	C and D > A and B
HOMA2-βcell	127,2	40,4	204,5	88,2	118,9	37,0	188,7	80,8	<0.001	B > A and C
HOMA2-S	81,9	44,6	41,0	27,3	80,6	36,9	32,8	10,5	<0.001	A and C > B and D
HOMA2-IR	1,5	0,5	3,2	1,6	1,4	0,4	3,5	1,6	<0.001	B and D > A and C
Insulin (μU/mL)	9,9	3,6	22,3	11,9	9,6	2,9	23,7	11,8	<0.001	B and D > A and C
Glucose (mg/dL)	89,3	10,1	94,9	22,7	91,9	11,3	103,2	28,9	<0.001	D > A, B and C
Total Cholesterol (mg/dL)	174,9	38,8	180,1	44,9	196,5	52,3	200,8	45,4	<0.001	D and C > A
Triglycerides (mg/dL) ¶	73.4	53.0–106.0	99.1	67.9–209.0	107.7	75.0–164.0	135.2	97.0–193.0	<0.001	C and D > A and B
HDL-C (mg/dL)										
Female	49,3	11,8	51,6	11,5	45,6	13,0	44,1	11,5	<0.001	B > C and D
Male	46,0	11,2	39,5	11,8	40,2	9,9	36,7	8,5	<0.001	A > B, C and D
VLDL-C (mg/dL)	17,1	9,3	31,0	28,5	26,7	20,4	32,5	21,5	<0.001	B and D > A
LDL-C (mg/dL)	109,8	34,5	106,4	40,2	126,3	35,1	128,0	37,2	<0.001	C and D > A and B
Lipoprotein(a) (mg/dL)	26,1	14,0	22,2	14,7	28,7	13,4	29,3	14,1	<0.001	C and D > B
hs-C Reactive Protein (mg/L) ¶	0.297	0.070–0.598	0.235	0.099–0.580	0.435	0.177–0.814	0.562	0.195–1.222	<0.001	C and D > A and B
Non HDL Cholesterol	126,9	38,6	135,3	45,5	153,8	51,9	160,3	45,1	<0.001	C and D > A and B
Triglycerides/HDL-C Index ¶	1.5	1.0–2.4	2.4	1.4–5.5	2.8	1.7–4.1	3.5	2.3–5.5	<0.001	C and D > A
Visceral Adiposity Index ¶	1.7	0.7–1.8	1.6	0.9–3.3	1.8	1.2–2.9	2.4	1.7–3.9	<0.001	D > A, B and C
Systolic Blood Pressure (mmHg)	111,9	13,3	115,2	15,3	125,3	18,4	125,6	17,3	<0.001	C and D > A and B
Diastolic Blood Pressure (mmHg)	71,7	9,4	73,9	10,9	81,5	12,3	81,9	11,2	<0.001	C and D > A and B

HNW (Healthy Normal Weight); MUNW (Metabolically Unhealthy Normal Weight); MHO (Metabolically Healthy Obese); MUO (Metabolically Unhealthy Obese).

SD=Standar Deviation;

* One-way ANOVA Test

¶ As Median (p25–p75th) Comparison: Kruskal Wallis Test

§ Pos-hoc Tukey analysis for means and ANOVA with Bonferroni correction for medians. Statistical significant difference (p<0.05)

Table 6. Logistic regression model for metabolic phenotypes and coronary risk categories. Maracaibo city, Venezuela.

	Crude Odds Ratio (IC 95% ^a)	<i>p</i> ^b	Adjusted Odds Ratio [*] (IC 95% ^a)	<i>p</i> ^b
Metabolic Phenotypes				
Metabolically Healthy Normal Weight	1,00	-	1,00	-
Metabolically Unhealthy Normal Weight	3,41 (1,46 - 7,98)	< 0,01	2.24 (0,89 - 5.56)	0,08
Metabolically Healthy Obese	2,26 (1,40 - 3,64)	< 0,01	1.85 (1.11 - 3.09)	0,02
Metabolically Unhealthy Obese	2,85 (1,89 - 4,29)	< 0,01	2.09 (1.34 - 3.28)	< 0,01

a Confidence Interval (95%); **b** Level of significance

Dependent Variable: Coronary risk: <5% in 10 years vs ≥5% in 10 years

^{*} Adjusted Model for: sex, age, ethnic group, socioeconomic status, smoking habit, physical activity in leisure dimension according to IPAQ, high TAG, and metabolic phenotypes.

“benign” state of the MHO adipose tissue, non-metabolic complications of obesity, do not exclude these subjects from getting T2DM, CVD, and chronic diseases associated with obesity in the future^{34,35}.

Healthy obese individuals must be classified in categories with higher risk of a coronary event compared to lean subjects. This is consistent with previous reports related to metabolic phenotypes and CVD, suggesting that healthy obese subjects have a higher risk profile in comparison to those with lower BMI³⁶; as well as an increased risk for CVD⁴⁷ and metabolic disorders such as fatty liver and low-grade inflammation⁷. Given the above, a profound evaluation of these patients is recommended. This includes not only obese subjects but also those who are overweight, which can go unnoticed in a routine consultation and CVD could be subclinical; as it has been demonstrated by Khan *et al.* in 475 women from the SWAN study⁴⁸.

Finally, despite the fact that our report presents a novel method to classify healthy and unhealthy subjects, it is important to mention the difficulty to follow-up these individuals. The latter would show the atypical phenotype stability related to time, as well as the incidence of T2DM and CVD. This was the main limitation of our study. In addition our study lacks nutritional data. For this reason, a thorough and constant evaluation of subjects with atypical metabolic phenotypes is recommended, given their demonstrated unsteadiness in time, and associated non metabolic comorbidities observed especially in the MHO individuals.

Data availability

Dataset 1: **MMSPS metabolic phenotype dataset**. BMI: Body Mass Index, WaistC: Waist Circumference, HDL-C: High Density Lipoprotein Cholesterol, VLDL-C: Very Low Density

Lipoprotein Cholesterol, LDL-C: Low Density Lipoprotein Cholesterol, Lp(a): Lipoprotein (a), hs-CRP: high Sensitivity C Reactive Protein, Non-HDL-Col: Non-High Density Lipoprotein Cholesterol, TAG/HDL ratio: Triglycerides/High Density Lipoprotein ratio VAI: Visceral Adiposity Index, BP: Blood Pressure, HNW: Healthy Normal-Weight, MUNW: Metabolically Unhealthy Normal-Weight, MUO: Metabolically Unhealthy Obese, MHO: Metabolically Healthy Obese. [10.5256/f1000research.13897.d193351](https://doi.org/10.5256/f1000research.13897.d193351)⁴⁹

Ethics and consent

The study was approved by the Bioethics Committee of the Endocrine and Metabolic Research Center – University of Zulia (approval number: BEC-006-0305). This ethical approval included all future studies that used the data from the Maracaibo City Metabolic Syndrome Prevalence Study (MMSPS). All participants signed written a informed consent for participation in the study before being questioned and physically examined by a trained team.

Abbreviations

CVD: cardiovascular disease

HDL-C: High Density Lipoprotein - Cholesterol

HNW: healthy normal-weight

HOMA: Homeostasis Model Assessment

HTN: hypertension

hs-CRP: high-sensitivity C-Reactive Protein

IR: insulin resistance

LDL-C: Low Density Lipoprotein – Cholesterol

MAP: mean arterial pressure

MET: Metabolic Equivalent

MMSPS: Maracaibo City Metabolic Syndrome Prevalence Study

MHO: metabolically healthy obese

MS: Metabolic Syndrome

MUNW: metabolically unhealthy normal-weight

MUO: metabolically unhealthy obese

PA: Physical activity

SD: standard deviation

TAG: triglycerides

T2DM: Type 2 Diabetes Mellitus

VAI: Visceral Adiposity Index

Grant information

This work was supported by research grant N° CC-0437-10-21-09-10 from the Technological, Humanistic, and Scientific Development Council (Consejo de Desarrollo Científico, Humanístico y Tecnológico; CONDES), University of Zulia.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- World Health Organization (WHO): **Obesity and overweight: Fact Sheet**. 2016; [cited 2017 Mar 20]. [Reference Source](#)
- Center for Disease Control and Prevention (CDC): **Adult Obesity Causes & Consequences | Overweight & Obesity**. 2016; [cited 2017 Mar 20]. [Reference Source](#)
- Andres R: **Effect of obesity on total mortality**. *Int J Obes*. 1980; 4(4): 381–6. [PubMed Abstract](#)
- Ferrannini E, Natali A, Bell P, *et al.*: **Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR)**. *J Clin Invest*. 1997; 100(5): 1166–73. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bernstein RS, Grant N, Kipnis DM: **Hyperinsulinemia and enlarged adipocytes in patients with endogenous hyperlipoproteinemia without obesity or diabetes mellitus**. *Diabetes*. 1975; 24(2): 207–13. [PubMed Abstract](#) | [Publisher Full Text](#)
- Ruderman NB, Schneider SH, Berchtold P: **The “metabolically-obese,” normal-weight individual**. *Am J Clin Nutr*. 1981; 34(8): 1617–21. [PubMed Abstract](#) | [Publisher Full Text](#)
- Shaharyar S, Roberson LL, Jamal O, *et al.*: **Obesity and metabolic phenotypes (metabolically healthy and unhealthy variants) are significantly associated with prevalence of elevated C-reactive protein and hepatic steatosis in a large healthy Brazilian population**. *J Obes*. 2015; 2015: 178526. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bermúdez V, Marcano RP, Cano C, *et al.*: **The Maracaibo city metabolic syndrome prevalence study: design and scope**. *Am J Ther*. 2010; 17(3): 288–94. [PubMed Abstract](#) | [Publisher Full Text](#)
- Bermúdez V, Rojas J, Salazar J, *et al.*: **Sensitivity and Specificity Improvement in Abdominal Obesity Diagnosis Using Cluster Analysis during Waist Circumference Cut-Off Point Selection**. *J Diabetes Res*. 2015; 2015: 750265. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mendez Castellano H, de Mendez MC: **Estratificación social y biología humana: metodo Graffar modificado**. *Arch Venez Pueric Pediatr*. 1986; 49(3–4): 93–104. [Reference Source](#)
- Chobanian AV, Bakris GL, Black HR, *et al.*: **The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report**. *JAMA*. 2003; 289(19): 2560–72. [PubMed Abstract](#) | [Publisher Full Text](#)
- World Health Organization (WHO): **The world health report 2003 - shaping the future**. 2003; [cited 2017 Nov 20]. [Reference Source](#)
- Center for Disease Control and Prevention (CDC): **Health Statistics, NHANES III Reference Manuals and Reports**. 1996; [cited 2017 Nov 20]. [Reference Source](#)
- Friedewald WT, Levy RI, Fredrickson DS: **Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge**. *Clin Chem*. 1972; 18(6): 499–502. [PubMed Abstract](#)
- Bermudez V, Salazar J, Martínez MS, *et al.*: **Prevalence and Associated Factors of Insulin Resistance in Adults from Maracaibo City, Venezuela**. *Adv Prev Med*. 2016; 2016: 9405105. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Levy JC, Matthews DR, Hermans MP: **Correct homeostasis model assessment (HOMA) evaluation uses the computer program**. *Diabetes Care*. 1998; 21(12): 2191–2. [PubMed Abstract](#) | [Publisher Full Text](#)
- Amato MC, Giordano C, Gallia M, *et al.*: **Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk**. *Diabetes Care*. 2010; 33(4): 920–2. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Alberti KG, Eckel RH, Grundy SM, *et al.*: **Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity**. *Circulation*. 2009; 120(16): 1640–5. [PubMed Abstract](#) | [Publisher Full Text](#)
- Bermúdez V, Salazar J, Bello L, *et al.*: **Coronary Risk Estimation According to a Recalibrated Framingham-Wilson Score in the Maracaibo City Metabolic Syndrome Prevalence Study**. *J Cardiol Phot*. 2014; 107: 160–8. [Reference Source](#)
- World Health Organization (WHO): **Global action plan for the prevention and control of NCDs 2013–2020**. 2013; [cited 2017 Nov 20]. [Reference Source](#)
- Hubert HB, Feinleib M, McNamara PM, *et al.*: **Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study**. *Circulation*. 1983; 67(5): 968–77. [PubMed Abstract](#) | [Publisher Full Text](#)
- Brochu M, Tchernof A, Dionne IJ, *et al.*: **What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women?** *J Clin Endocrinol Metab*. 2001; 86(3): 1020–5. [PubMed Abstract](#) | [Publisher Full Text](#)
- Stefan N, Kantartzis K, Machann J, *et al.*: **Identification and characterization of metabolically benign obesity in humans**. *Arch Intern Med*. 2008; 168(15): 1609–16. [PubMed Abstract](#) | [Publisher Full Text](#)
- Aguilar-Salinas CA, García EG, Robles L, *et al.*: **High adiponectin concentrations are associated with the metabolically healthy obese phenotype**. *J Clin Endocrinol Metab*. 2008; 93(10): 4075–9. [PubMed Abstract](#) | [Publisher Full Text](#)
- Martínez-Larrad MT, Corbatón Anchuelo A, Del Prado N, *et al.*: **Profile of individuals who are metabolically healthy obese using different definition criteria. A population-based analysis in the Spanish population**. *PLoS One*. 2014; 9(9): e106641. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lee K: **Metabolically obese but normal weight (MONW) and metabolically healthy but obese (MHO) phenotypes in Koreans: characteristics and health behaviors**. *Asia Pac J Clin Nutr*. 2009; 18(2): 280–4. [PubMed Abstract](#)
- Zheng R, Yang M, Bao Y, *et al.*: **Prevalence and Determinants of Metabolic Health in Subjects with Obesity in Chinese Population**. *Int J Environ Res Public Health*. 2015; 12(11): 13662–77. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Calori G, Lattuada G, Piemonti L, *et al.*: **Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study**. *Diabetes Care*. 2011; 34(1): 210–5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lopez-Garcia E, Guallar-Castillon P, Leon-Muñoz L, *et al.*: **Prevalence and**

- determinants of metabolically healthy obesity in Spain. *Atherosclerosis*. 2013; 231(1): 152–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Hamer M, Bell JA, Sabia S, *et al.*: **Stability of metabolically healthy obesity over 8 years: the English Longitudinal Study of Ageing.** *Eur J Endocrinol*. 2015; 173(5): 703–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Kuk JL, Ardern CI: **Are metabolically normal but obese individuals at lower risk for all-cause mortality?** *Diabetes Care*. 2009; 32(12): 2297–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Wildman RP, Muntner P, Reynolds K, *et al.*: **The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004).** *Arch Intern Med*. 2008; 168(15): 1617–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Fanghanel-Salmón G, Gutiérrez-Salmeán G, Samaniego V, *et al.*: **Obesity Phenotypes In Urban Middle-Class Cohorts; The Prit-Lindavista Merging Evidence In Mexico: The Opus Prime Study.** *Nutr Hosp*. 2015; 32(1): 182–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Bo S, Musso G, Gambino R, *et al.*: **Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort.** *Am J Clin Nutr*. 2012; 96(5): 962–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Hinnouho GM, Czernichow S, Dugravot A, *et al.*: **Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study.** *Eur Heart J*. 2015; 36(9): 551–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Yoo HK, Choi EY, Park EW, *et al.*: **Comparison of Metabolic Characteristics of Metabolically Healthy but Obese (MHO) Middle-Aged Men According to Different Criteria.** *Korean J Fam Med*. 2013; 34(1): 19–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 37. Schmiegelow MD, Hedlin H, Mackey RH, *et al.*: **Race and ethnicity, obesity, metabolic health, and risk of cardiovascular disease in postmenopausal women.** *J Am Heart Assoc*. 2015; 4(5): pii:e001695.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 38. Yang HK, Han K, Kwon HS, *et al.*: **Obesity, metabolic health, and mortality in adults: a nationwide population-based study in Korea.** *Sci Rep*. 2016; 6(6): 30329.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Diniz Mde F, Beleigoli AM, Ribeiro AL, *et al.*: **Factors associated with metabolically healthy status in obesity, overweight, and normal weight at baseline of ELSA-Brasil.** *Medicine (Baltimore)*. 2016; 95(27): e4010.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Ortega FB, Lee DC, Katzmarzyk PT, *et al.*: **The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness.** *Eur Heart J*. 2013; 34(5): 389–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Romero-Corral A, Somers VK, Sierra-Johnson J, *et al.*: **Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality.** *Eur Heart J*. 2010; 31(6): 737–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. Madeira FB, Silva AA, Veloso HF, *et al.*: **Normal weight obesity is associated with metabolic syndrome and insulin resistance in young adults from a middle-income country.** *PLoS One*. 2013; 8(3): e60673.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Succurro E, Marini MA, Frontoni S, *et al.*: **Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals.** *Obesity (Silver Spring)*. 2008; 16(8): 1881–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Ogorodnikova AD, Kim M, McGinn AP, *et al.*: **Incident cardiovascular disease events in metabolically benign obese individuals.** *Obesity (Silver Spring)*. 2012; 20(3): 651–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Hansen L, Netterstrøm MK, Johansen NB, *et al.*: **Metabolically Healthy Obesity and Ischemic Heart Disease: A 10-Year Follow-Up of the Inter99 Study.** *J Clin Endocrinol Metab*. 2017; 102(6): 1934–1942.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Kim NH, Seo JA, Cho H, *et al.*: **Risk of the Development of Diabetes and Cardiovascular Disease in Metabolically Healthy Obese People: The Korean Genome and Epidemiology Study.** *Medicine (Baltimore)*. 2016; 95(15): e3384.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Durward CM, Hartman TJ, Nickols-Richardson SM: **All-cause mortality risk of metabolically healthy obese individuals in NHANES III.** *J Obes*. 2012; 2012: 460321.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Khan UI, Wang D, Thurston RC, *et al.*: **Burden of subclinical cardiovascular disease in “metabolically benign” and “at-risk” overweight and obese women: the Study of Women’s Health Across the Nation (SWAN).** *Atherosclerosis*. 2011; 217(1): 179–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 49. Bermudez V, Rojas J, Salazar J, *et al.*: **Dataset 1 in: Biochemical and clinical characterization of metabolic phenotypes: a cross-sectional study from Maracaibo city, Venezuela.** *F1000Research*. 2018.
<http://www.doi.org/10.5256/f1000research.13897.d193351>

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 03 September 2020

<https://doi.org/10.5256/f1000research.19357.r70666>

© 2020 Müller M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Manfred J. Müller

Institute of human nutrition and food science, Christian Albrechts Universität zu Kiel, Kiel, Germany

My major concern is about the general idea of a metabolically healthy obese subjects. This is an arbitrary rather than a biological phenotype. BMI (and also fat mass) have a limited precision to estimate metabolic risks, i.e., the respective ROC estimates are around 0.7. Since obesity is about categorization (based on observational data on the association between BMI and mortality risk) the finding that about 30% of obese subjects have no measurable metabolic risks question that clinical categorization rather than generating a specific metabolic phenotype worthwhile to study in detail. Thus, the true message of the present paper should be about a metabolically based categorization of the BMI. To get the idea the authors are referred to e.g., *Obes Sci & Pract* 2017¹.

References

1. Hübers M, Pourhassan M, Braun W, Geisler C, et al.: Definition of new cut-offs of BMI and waist circumference based on body composition and insulin resistance: differences between children, adolescents and adults. *Obes Sci Pract.* **3** (3): 272-281 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Metabolism, phenotyping

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Reviewer Report 22 January 2019

<https://doi.org/10.5256/f1000research.19357.r42581>

© 2019 Cortes V. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Víctor A. Cortes

Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontifical Catholic University of Chile (UC), Santiago, Chile

I believe the current version of the paper fully addresses my comments.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 19 July 2018

<https://doi.org/10.5256/f1000research.15107.r35881>

© 2018 Cortes V. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Víctor A. Cortes

Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontifical Catholic University of Chile (UC), Santiago, Chile

The authors aimed to estimate the prevalence of “atypical metabolic phenotypes” i.e. lean metabolically unhealthy and obese metabolically healthy individuals in the city area of Maracaibo, Venezuela. For that, they analyzed previously generated data from a cross-sectional city-wide health survey (MMSPS), grouping individuals in three BMI categories (normal weight, overweight and obese) and in two “metabolic health” categories (healthy and unhealthy).

Overall, this study is incremental, reporting no new scientific information on the metabolic phenotypes whatsoever. Its relevance relies on the fact that it is a methodologically correct study of a Latin American population, which is largely underrepresented in the international literature.

Nevertheless, there are several specific caveats that must be addressed before the article be suitable for indexing:

Abstract:**Methodology:**

1. It must tell the source of the sample to make clear that it is a city-wide health survey.
2. It must indicate what were the specific criteria for this clustering of individuals in healthy/unhealthy categories. It is not enough to tell that it was made upon a 2-step clustering analysis.

Results:

1. It should be rewritten to clearly indicate the frequency of each phenotype category and indicate if there were differences between the sexes in this distribution and the OR for cardiovascular risk factors or diseases.
2. It must indicate what is the difference between unhealthy lean and unhealthy normal-weight individuals

Conclusions: There are no reasons to suppose that individuals of Maracaibo city will have no “atypical metabolic phenotypes” as the rest of the world populations, thus the authors should rephrase this sentence to make more scientifically sound. Also, the conclusion relative to the

increased cardiovascular risk of “healthy obese” individuals should be better explained since it cannot be derived from the data reported in the Results section of the abstract.

Introduction:

The phrase: “For this reason, the actual clinical practice catalogues an obese patient as an “unhealthy” patient and a lean patient is considered “healthy”, should be modified to make its medical meaning clearer, because it is evident for everybody that many lean people are unhealthy.

Also, the paper will gain interest if the authors comment what is the importance of researching the “atypical phenotypes” in general. For example, is there any evidence that these individuals can be misclassified in their cardiometabolic risk based solely in the BMI?

Finally, it is important that the authors comment the extent to what Maracaibo city population is representative of other Latin American populations. For international readers will be interesting to learn that American populations are extremely heterogenous in both genetic and cultural aspects.

Materials and methods:

“Population selection”: this whole methodological section is cryptic and is basically a summary of the published in the reference 9. I suggest to re write it to make more understandable for general readers. Specifically, it must be justified why the authors did choose not to use more a conventional definition of metabolic health, such as the metabolic syndrome definition used by ATP III guidelines.

“Physical activity”: it should be improved the explanation of what is the relevance and connection of table 1 with the rest of the paper. Also, in this table there is no quantitative definition of the “Work domain” and “lower/upper limit” categories. Information of the proportion of each category over the overall would be useful to summarize these data.

“Calibration of the Framingham-Wilson equation and coronary risk categorization for the population of Maracaibo city”: the authors must explain what asymptomatic angina is, since medically angina is a symptom by itself.

Results:

Table 2: change “Indian-american” for “native American”, if its corresponds since “Indian” correspond to India nationals

“Metabolic phenotypes and biologic-anthropometric variables” section: Since all the variables in this table are statistically different, a post test comparing individual groups should be important to make sense of the noted global differences.

Also, a better description and explanation of these particular results is required in the main text.

“Metabolic phenotypes and coronary risk classification” section: the meaning of the first phrase must be clarified since only obese individuals showed increased OR: other comparisons were not statistically significant with the adjusted model, thus were not different.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Basic and clinical research on adipose tissue disorders, diabetes, dyslipidemia and fatty liver

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research